Leonie Schneider, a passionate mental health advocate, is committed to expanding access to psychedelic assisted therapies by advocating for the safe and integrated use of psychedelics. After participating in a Psilocybin for Depression trial at Imperial College (2019) and Small Pharma’s DMT for Depression trial (2022), she co-founded the Psychedelic Participant Advocacy Network (PsyPAN) to help inform the delivery of trial and treatment design from a participant perspective. Leonie’s recognition as one of the top 20 influential, innovative, and disruptive women in psychedelics speaks to her commitment to enhancing participant well-being and improved outcomes.
Ian Roullier is the co-founder of the Psychedelic Participant Advocacy Network (PsyPAN). Ian’s participation in clinical trials run by Imperial College (2015) and King’s College/Compass Pathways (2019), both examining the effect of psilocybin on depression, naturally led to his dedication to helping bring these treatments safely to all who may benefit from them. PsyPAN works with organisations providing psychedelic-assisted therapy with the aim of helping create a sector-wide model of best practice with participant wellbeing placed at its heart, and also aims to provide much-needed community and connection for people who have received these treatments.